{"entity":{"id":"jennifer-brown","kind":"person","name":"Jennifer R. Brown","aka":[],"tldr":"Led ALPINE, the first head-to-head trial in which a next-generation BTK inhibitor (zanubrutinib) beat ibrutinib.","summary":"Jennifer Brown was principal investigator of ALPINE, which showed zanubrutinib improves progression-free survival and causes fewer cardiac events than ibrutinib in relapsed CLL, and led early work on idelalisib and the genetics of familial CLL. She directs the CLL centre at Dana-Farber and leads trials of non-covalent BTK inhibitors and BTK degraders for resistant disease.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brown%20JR%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20zanubrutinib"}],"tags":["cll","btk","trialist"],"related":[],"cancers":["cll"],"sections":[],"technologies":["kinase-inhibitors","protac-degrader"],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["alpine","bruin-cll-321"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, CLL Center, Dana-Farber Cancer Institute; Worthington and Margaret Collette Professor of Medicine, Harvard Medical School","institutionId":"dana-farber","specialisms":["Chronic lymphocytic leukaemia","BTK inhibitors","CLL genetics","Novel agents"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brown%20JR%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20zanubrutinib"}],"papers":[{"title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia (ALPINE)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2211582"},{"title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia","journal":"Blood","year":2014,"doi":"10.1182/blood-2013-11-535047"}]},"route":"/people/jennifer-brown/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"technology":[{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"}],"trial":[{"id":"alpine","kind":"trial","name":"ALPINE","route":"/trials/alpine/"},{"id":"bruin-cll-321","kind":"trial","name":"BRUIN CLL-321","route":"/trials/bruin-cll-321/"}]}}